Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ResMed (RMD)

ResMed reports 9% revenue rise to $1.3 billion for quarter ended September 30, 2025

Positive Impact 3 of 5 earnings Written later

ResMed reported first-quarter fiscal 2026 results with revenue up 9% to $1.3 billion and diluted earnings per share of $2.37, up 12% from $2.11 a year earlier. The company also declared a quarterly dividend of $0.60 per share, payable December 18, 2025, which is the figure shareholders will receive per common share.

Key points

  • Revenue rose 9% to $1.3 billion ($1,335.6 million), or 8% on a constant currency basis.
  • Diluted EPS was $2.37 versus $2.11; non-GAAP diluted EPS was $2.55 versus $2.20, up 16%.
  • Restructuring charges of $16 million were recorded following company-wide workforce planning.
  • Quarterly cash dividend of $0.60 per share; record date November 13, 2025; ex-dividend date November 12, 2025.

The filing

CompanyResMed (RMD)
Form8-K, current report
Filed with the SECOct 30, 2025, 4:06 PM ET
Accession number0001193125-25-258519

Items reported: 2.02 Results of Operations8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:30 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 30, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.